Results 61 to 70 of about 10,730,025 (313)

Cognition in neuromuscular disease

open access: yesJournal of Pediatric Rehabilitation Medicine, 2008
Although neuromuscular diseases primarily affect an individual's physical functioning, the cognitive and psychosocial effects of these conditions can be quite significant. This paper provides an overview of a subset of neuromuscular diseases and their associated neurocognitive risks.
Angela Giacoletti, Argento   +1 more
openaire   +2 more sources

RNA Sequencing Resolves Cryptic Pathogenic Variants in Mitochondrial Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Mitochondrial diseases are the most common inherited metabolic disorders, characterized by pronounced clinical and genetic heterogeneity that complicates molecular diagnosis. Although DNA‐based sequencing approaches have become standard in genetic testing, up to half of patients remain without a definitive diagnosis.
Zhimei Liu   +21 more
wiley   +1 more source

Digital Monitoring of Patients with Generalized Myasthenia Gravis: A Prospective Pilot Study

open access: yesNeurology and Therapy
Introduction Monitoring patients with myasthenia gravis (MG) can be challenging due to the fluctuating nature of the disease. We aimed to test the reliability of using the MG Activities of Daily Living (MG-ADL) scale in the form of a smartphone ...
Ana Vesperinas   +10 more
doaj   +1 more source

Maximum inspiratory pressure as a clinically meaningful trial endpoint for neuromuscular diseases: a comprehensive review of the literature

open access: yesOrphanet Journal of Rare Diseases, 2017
Respiratory muscle strength is a proven predictor of long-term outcome of neuromuscular disease (NMD), including amyotrophic lateral sclerosis, Duchenne muscular dystrophy, and spinal muscular atrophy.
B. Schoser   +10 more
semanticscholar   +1 more source

Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane   +19 more
wiley   +1 more source

Splicing therapy for neuromuscular disease [PDF]

open access: yesMolecular and Cellular Neuroscience, 2013
Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA) are two of the most common inherited neuromuscular diseases in humans. Both conditions are fatal and no clinically available treatments are able to significantly alter disease course in either case.
Douglas, Andrew G.L., Wood, Matthew J.A.
openaire   +4 more sources

Early Clinical, Imaging, and Pathological Characteristics of SRPK3/TTN‐Digenic Myopathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective SRPK3/TTN‐digenic myopathy was recently established as a skeletal muscle myopathy caused by digenic inheritance. This study characterizes the early clinical presentation of SRPK3/TTN‐digenic myopathy in one previously reported and seven newly identified pediatric patients.
Rotem Orbach   +23 more
wiley   +1 more source

A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases

open access: yesOrphanet Journal of Rare Diseases, 2021
Background Due to their health condition, patients with neuromuscular diseases (NMD) are at greater risk of developing serious complications with COVID-19.
Lucie Isoline Pisella   +44 more
doaj   +1 more source

NEUROLOGICAL AND NEUROMUSCULAR DISEASE

open access: yesBritish Journal of Anaesthesia, 1986
Aspects du controle nerveux de la respiration. Syndrome de Guillain Barre. Myasthenie.
openaire   +2 more sources

Long‐Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy—A 10‐Year Follow Up Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Autoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long‐term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long‐term treatment response, residual autonomic dysfunction, and relapse patterns in patients with
Giacomo Chiaro   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy